Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ, Brown A, Dylla DE, Dillon JF, Luetkemeyer AF, Feld JJ, Mutimer D, Ghalib R, Crown E, Lovell SS, Hu Y, Moreno C, Nelson DR, Colombo M, Papatheodoridis G, Rockstroh JK, Skoien R, Lawitz E, Jacobson IM. Zamor PJ, et al. Among authors: mutimer d. Am J Gastroenterol. 2021 Sep 1;116(9):1896-1904. doi: 10.14309/ajg.0000000000001332. Am J Gastroenterol. 2021. PMID: 34465693 Free PMC article.
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group. Zoutendijk R, et al. Among authors: mutimer d. Hepatology. 2011 Aug;54(2):443-51. doi: 10.1002/hep.24406. Hepatology. 2011. PMID: 21563196 Clinical Trial.
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. Ramachandran P, et al. Among authors: mutimer dj. Aliment Pharmacol Ther. 2012 Mar;35(6):647-62. doi: 10.1111/j.1365-2036.2012.04992.x. Epub 2012 Feb 1. Aliment Pharmacol Ther. 2012. PMID: 22296568 Free article.
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Arends P, et al. Among authors: mutimer d. Gut. 2015 Aug;64(8):1289-95. doi: 10.1136/gutjnl-2014-307023. Epub 2014 Jul 10. Gut. 2015. PMID: 25011935 Clinical Trial.
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X; SOLAR-2 investigators. Manns M, et al. Among authors: mutimer d. Lancet Infect Dis. 2016 Jun;16(6):685-697. doi: 10.1016/S1473-3099(16)00052-9. Epub 2016 Feb 18. Lancet Infect Dis. 2016. PMID: 26907736 Clinical Trial.
Flares during long-term entecavir therapy in chronic hepatitis B.
Chi H, Arends P, Reijnders JG, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen BE, Janssen HL; VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance). Chi H, et al. Among authors: mutimer d. J Gastroenterol Hepatol. 2016 Nov;31(11):1882-1887. doi: 10.1111/jgh.13377. J Gastroenterol Hepatol. 2016. PMID: 27008918
Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.
Forns X, Didier S, Mutimer D, Fagiuoli S, Navasa M, Agarwal K, Berenguer M, Colombo M, Herzer K, Nevens F, Daems B, Janssen K, Ouwerkerk-Mahadevan S, Kimko H, Lathouwers E, Witek J, Van Solingen-Ristea R. Forns X, et al. Among authors: mutimer d. Ann Hepatol. 2016 Jul-Aug;15(4):512-23. Ann Hepatol. 2016. PMID: 27236150 Free article. Clinical Trial.
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.
Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ. Puoti M, et al. Among authors: mutimer d. J Hepatol. 2018 Aug;69(2):293-300. doi: 10.1016/j.jhep.2018.03.007. Epub 2018 Mar 16. J Hepatol. 2018. PMID: 29551706 Free article. Clinical Trial.
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, Gane E, Kao JH, Mantry PS, Mutimer D, Reddy KR, Tran TT, Hu YB, Gulati A, Krishnan P, Dumas EO, Porcalla A, Shulman NS, Liu W, Samanta S, Trinh R, Forns X. Reau N, et al. Among authors: mutimer d. Hepatology. 2018 Oct;68(4):1298-1307. doi: 10.1002/hep.30046. Epub 2018 Jul 25. Hepatology. 2018. PMID: 29672891 Free PMC article. Clinical Trial.
220 results